Stryker Corporation 10-Q Summary: Period Ended June 30, 2002
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2002, for Stryker Corporation, a medical technology company. The registrant operates primarily through two reportable segments: Orthopaedic Implants and MedSurg Equipment. The financial statements are unaudited and prepared in accordance with GAAP for interim reporting.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2002 | Six Months Ended June 30, 2001 | Three Months Ended June 30, 2002 |
|---|---|---|---|
| Net Sales | $1,436.8 million | $1,273.2 million | $733.9 million |
| Gross Profit | $914.8 million (63.7% margin) | $803.6 million (63.1% margin) | $466.8 million (63.6% margin) |
| Net Earnings | $167.0 million | $129.8 million | $85.9 million |
| Diluted EPS | $0.82 | $0.64 | $0.42 |
| Operating Cash Flow | $172.8 million | $152.0 million | N/A |
| Cash and Equivalents | $52.2 million | N/A | N/A |
| Long-Term Debt | $617.6 million (Total) | N/A | N/A |
| Working Capital | $540.7 million | $459.7 million (Dec 31, 2001) | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13% year-over-year for the six-month period, driven by a 10% increase in unit volume/mix, 3% price increases, and 1% from acquisitions. Domestic sales grew 15%, while international sales grew 9% (12% excluding currency impacts).
- Profitability: Net earnings rose 29% to $167.0 million. Gross margins improved slightly due to increased production absorbing manufacturing costs.
- Expense Management: Interest expense declined significantly (43% reduction for six months) due to lower debt balances. Intangibles amortization decreased due to the adoption of FASB Statement No. 142, which eliminated goodwill amortization.
- Segment Performance: Orthopaedic Implants sales grew 13% (15% excluding currency), and MedSurg Equipment sales grew 12% (13% excluding currency).
Outlook, Risks, and Unusual Items
- Acquisition: On July 1, 2002, Stryker acquired the spinal implant business of Surgical Dynamics Inc. for $135.0 million. The impact on net earnings is expected to be neutral in 2002 and accretive in 2003.
- Restructuring: The company announced a tentative decision to close its Rutherford, New Jersey, implant manufacturing facility. A tentative union agreement reached in August 2002 anticipates after-tax employment-related closing costs of approximately $15.0 million, expected to be expensed in the third quarter of 2002.
- Accounting Changes: Adoption of FASB No. 142 increased net earnings by $5.3 million for the first six months of 2002 by eliminating goodwill amortization. The company performed its initial goodwill impairment test and found no impairment.
- Liquidity: The company maintains $477.3 million in additional borrowing capacity. Management believes cash on hand and operating cash flows are sufficient for future needs.
- Risks: Forward-looking statements are subject to risks including regulatory cost-containment measures, reimbursement level changes, product liability claims, and foreign exchange fluctuations.
Investor Verification Checklist
- Verify the final ratification of the union agreement regarding the Rutherford facility closure and the timing of the $15.0 million charge.
- Monitor the integration progress and financial contribution of the Surgical Dynamics Inc. acquisition starting in Q3 2002.
- Review the impact of foreign currency exchange rates on international sales, which showed a 1% negative impact in the first six months.
- Confirm the trajectory of inventory levels, which increased to 149 days sales outstanding, partly due to the Rutherford facility closure preparations.
- Assess the sustainability of gross margin improvements driven by production volume absorption.